A Detail View of Single-Use Equipment Opportunities - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

A Detail View of Single-Use Equipment Opportunities
The authors propose increased use of single-use technologies in biopharmaceutical manufacturing to achieve operational excellence without compromising product quality.

Pharmaceutical Technology
Volume 34, pp. s16-s20

Figure 1: Single-use cell culture system. (ALL FIGURES ARE COURTESY OF THE AUTHORS)
Patent expirations, stiff competition, plant utilization, product safety, and supply assurance are some of the challenges facing the biopharmaceutical industry. The manufacturing landscape has changed dramatically during the past several years—and it's still evolving.

Novel approaches for treating specific diseases such as cancer are very promising. However, the days of biotechnology innovations being measured purely on gaining blockuster status (i.e., reaching more than $1 billion in revenues) are largely gone. The capacity constraints predicted in the late 1990s, combined with insufficient development pipelines and tougher regulations, caused a major market consolidation, evidenced by acquisitions, alliances, and outsourcing.

Similar to what the semiconductor industry already experienced, drug manufacturers face a changing environment that requires innovation and efficiency. They must manufacture products economically and efficiently while also improving quality and safety. Understanding cost drivers within the manufacturing and development processes is key to assessing the impact of new business models and technologies.

The costs associated with constructing and operating manufacturing capacities as applied to clinical phases and large-scale manufacturing call for challenging current paradigms. Single-use technologies represent one option to achieve operational excellence without compromising quality.

Single-use technologies are being used more in biopharmaceutical manufacturing and that use is expected to increase substantially in the coming years. With the further penetration of disposables into larger volumes and more critical areas of the biomanufacturing process, however, companies involved in biopharmaceutical development and the production of new molecules must closely examine the advantages, limitations, and facility implications of single-use manufacturing scenarios.

The challenge is to design and implement application-specific, integrated-process solutions that follow the same principles as conventional process designs regarding quality, engineering, automation, and control. Single-use technologies are not an "one-size-fits-all" solution. They must be intelligently integrated into process designs.

Figure 2: Single-use unit operation.
Process analytical technologies (PAT) and quality by design (QbD) are major initiatives in the industry that will influence the future technology penetration significantly. It's important to examine additional improvement opportunities offered by the increased implementation of single-use solutions to exploit advantages. Production facilities, traditionally, were built to house stainless steel-based production scenarios. Does this mean that new facilities are required to be built the same way? What about cleanroom classifications to operate individual process units? Single-use solutions are presterilized, closed systems that can reduce, if not eliminate the need for extensive cleaning and steaming utilities. Aseptic-processing requirements that benefit from single-use solutions through the reduction of cross-contamination successfully support the shift to multipurpose manufacturing designs and concepts. One might think that disposing such solutions adversely affects carbon-footprint evaluation. However, there is no standardized approach to such calculations and studies published in the past two years demonstrate that the opposite is true. The authors contend that understanding the advantages provided by single-use technologies, mitigating the limitations, and exploring new opportunities is the most-appropriate approach for operational excellence.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here